Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neurofibromatosis 1 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Magnetic Resonance Spectroscopy 23Temozolomide 22Specimen Handling 13Radiotherapy 12Biopsy 9X-Rays 8Radiation 8trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4abemaciclib 4ulixertinib 3palbociclib 3olaparib 3Surgical Procedures, Operative 3Nivolumab 3D2C7-(scdsFv)-PE38KDEL 3Cyclophosphamide 3tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × lorlatinib × 90 days × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡